Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities to various EGFR‐TKI hav...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Banno, Eri, Togashi, Yosuke, Nakamura, Yu, Chiba, Masato, Kobayashi, Yoshihisa, Hayashi, Hidetoshi, Terashima, Masato, de Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko, Mitsudomi, Tetsuya, Nishio, Kazuto
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2016
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982590/
https://ncbi.nlm.nih.gov/pubmed/27240419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12980
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk